Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: June 22, 2018
Event: Partial redemption of outstanding debt securities.
Key Financial Metrics
This filing reports a specific debt transaction rather than comprehensive financial performance metrics (revenue, profit, cash flow, or margins). The filing text does not provide a clear value for these operational metrics.
| Metric | Value |
|---|---|
| Notes Redeemed | $1,300,000,000 |
| Notes Remaining Outstanding | $495,500,000 |
| Original Aggregate Principal | $1,795,500,000 |
| Interest Rate | 2.350% |
| Redemption Price | 100.000% of principal plus accrued interest |
Material Changes
On June 22, 2018, Abbott Laboratories executed a partial redemption of its 2.350% Notes due 2019. This action reduced the total outstanding principal of this specific debt instrument by approximately 72.4%, leaving $495.5 million outstanding.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of new risks or contingencies. The transaction was executed in accordance with the terms of the Indenture dated March 10, 2015, as amended.
Investor Verification Checklist
- Verify the remaining debt schedule for the 2.350% Notes due 2019 ($495.5 million).
- Confirm the cash outflow impact of the redemption on the company's liquidity position for the quarter.
- Review the Indenture terms to ensure no other covenants were triggered by this partial redemption.
- Check subsequent filings for any additional debt repayments or refinancing activities.